Roth Capital analyst Boobalan Pachaiyappan initiated coverage of Immunic (IMUX) with a Buy rating and $3 price target The firm says the company has “potential best-in-indication advantages” of vidofludimus calcium in relapsing-remitting multiple sclerosis and progressive multiple sclerosis. This is validated by Immunic’s Phase 2 data that demonstrated simultaneous anti-inflammation and neuroprotection, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMUX: